CHARLES RIVER LABORATORIES INTERNATIONAL, INC. Derivative Asset
CHARLES RIVER LABORATORIES INTERNATIONAL, INC. (CRL) had Derivative Asset of $778.00 thousand as of 2019-09-28, per its 10-Q filed 2019-11-06.
Discontinued › Balance Sheet › Assets
us-gaap:DerivativeAssets · last filed 2019-11-06
- 2019-09-28: Derivative Asset $778.00K.
- 2018-09-29: Derivative Asset $29.00K.
| Period end | Derivative Asset |
|---|---|
| 2019-09-28 | $778.00K 10-Q · filed 2019-11-06 |
| 2018-09-29 | $29.00K 10-Q · filed 2018-11-07 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Medpace Holdings, Inc. (MEDP) | United States | $17.316B | 30.09 |
| INCYTE CORP (INCY) | United States | $24.855B | 13.14 |
| Absci Corp (ABSI) | United States | $1.775B | -14.92 |
| OmniAb, Inc. (OABI) | United States | $0.698B | -8.05 |
| NRC HEALTH (NRC) | United States | $0.450B | 42.50 |
| MAXCYTE, INC. (MXCT) | United States | $0.124B | -3.68 |
| bioAffinity Technologies, Inc. (BIAF) | United States | $0.063B | |
| OneMedNet Corp (ONMD) | $0.042B | ||
| iSpecimen Inc. (ISPC) | United States | $0.003B | |
| FOXO TECHNOLOGIES INC. (FOXO) | United States | $0.000B | -277.71 |